TrialBreast cancer research and treatment2013

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.

Alvaro Moreno-Aspitia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.